Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Lymphoma, Follicular 6Prostatic Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Urinary Bladder Neoplasms 1Sarcoma, Synovial 1Sarcoma 1Rhabdoid Tumor 1Multiple Myeloma 1Mesothelioma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Hematologic Neoplasms 1Chordoma 1Carcinoma, Transitional Cell 1

Interventions

Gemcitabine 15pembrolizumab 13Doxorubicin 13Radiotherapy 12Docetaxel 9Nivolumab 8Filgrastim 7Cyclophosphamide 7pazopanib 6Ifosfamide 6130-nm albumin-bound paclitaxel 5Temozolomide 4Irinotecan 4Ipilimumab 4Imatinib Mesylate 4Albumin-Bound Paclitaxel 4talimogene laherparepvec 3surufatinib 3pegfilgrastim 3eribulin 3atezolizumab 3Vinorelbine 3Sirolimus 3Peripheral Blood Stem Cell Transplantation 3PM 01183 3Drug Therapy 3Cisplatin 3toripalimab 2spartalizumab 2selinexor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Sarcoma × tazemetostat × Clear all
NCT05407441 2026-04-13

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

Dana-Farber Cancer Institute

Phase 1/2 Active not recruiting
49 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡